Axovan Overview

  • Founded
  • 2000
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $43.9M
Latest Deal Amount

Axovan General Information


Operator of a biopharmaceutical research company intended to create novel drugs. The company is involved in the discovery of drugs linked to G protein-coupled receptors, enabling patients to receive drugs at a short span of time.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Gewerbestrasse 16
  • 4123 Allschwil
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Axovan Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Oct-2003 $43.9M 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 22-Apr-2002 0000 000.00 Completed Generating Revenue
1. Early Stage VC 01-Jun-2000 $4.68M $4.68M Completed Product Development
To view Axovan’s complete valuation and funding history, request access »

Axovan Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atlas Venture Venture Capital Minority 000 0000 000000 0
Banque Cantonale Vaudoise Corporation Minority 000 0000 000000 0
Endeavour Vision Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
Heidelberg Innovation Fonds Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »